|

Pembrolizumab 200 mg Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Arm F, KEYTRUDA®, MK-3475

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1
  • Melanoma Institute Australia1

Indications

  • Cancer2
  • Mucosal Melanoma1
  • Metastatic Castration-resistant Prostate Cancer1
  • Cutaneous Melanoma1

Other1 trial

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2

Aurora, Colorado1 trial

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Call for Information (Investigational Site 2041)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.